FDA Alerts

FDA approves momelotinib for myelofibrosis patients with anemia

The US Food and Drug Administration has approved momelotinib (Ojjaara; GSK) for treating intermediate or high-risk myelofibrosis in adults with anemia, according to a press release. It is currently the only approved medication for both newly diagnosed and previously treated myelofibrosis patients with anemia, effectively addressing major symptoms of the disease...